$433.45
0.84% yesterday
Nasdaq, Oct 15, 10:00 pm CET
ISIN
US5588681057
Symbol
MDGL

Madrigal Pharmaceuticals, Inc. Stock price

$433.45
+7.85 1.84% 1M
+112.35 34.99% 6M
+124.88 40.47% YTD
+217.28 100.51% 1Y
+363.17 516.75% 3Y
+309.96 251.00% 5Y
+362.05 507.07% 10Y
+115.30 36.24% 20Y
Nasdaq, Closing price Wed, Oct 15 2025
-3.65 0.84%
ISIN
US5588681057
Symbol
MDGL
Industry

Key metrics

Basic
Market capitalization
$9.7b
Enterprise Value
$9.0b
Net debt
positive
Cash
$797.0m
Shares outstanding
22.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
18.7 | 10.9
EV/Sales
17.4 | 10.1
EV/FCF
negative
P/B
13.9
Financial Health
Equity Ratio
72.4%
Return on Equity
-61.8%
ROCE
-37.8%
ROIC
-
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$515.6m | $890.0m
EBITDA
$-308.4m | $-264.1m
EBIT
$-309.8m | $-276.0m
Net Income
$-281.9m | $-227.4m
Free Cash Flow
$-308.4m
Growth (TTM | estimate)
Revenue
3,421.5% | 394.1%
EBITDA
41.8% | 46.8%
EBIT
41.6% | 44.6%
Net Income
44.8% | 51.2%
Free Cash Flow
32.3%
Margin (TTM | estimate)
Gross
96.3%
EBITDA
-59.8% | -29.7%
EBIT
-60.1%
Net
-54.7% | -25.6%
Free Cash Flow
-59.8%
More
EPS
$-12.7
FCF per Share
$-13.9
Short interest
19.4%
Employees
528
Rev per Employee
$340.0k
Show more

Is Madrigal Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Madrigal Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a Madrigal Pharmaceuticals, Inc. forecast:

19x Buy
86%
2x Hold
9%
1x Sell
5%

Analyst Opinions

22 Analysts have issued a Madrigal Pharmaceuticals, Inc. forecast:

Buy
86%
Hold
9%
Sell
5%

Financial data from Madrigal Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
516 516
3,422% 3,422%
100%
- Direct Costs 19 19
2,897% 2,897%
4%
496 496
3,446% 3,446%
96%
- Selling and Administrative Expenses 614 614
136% 136%
119%
- Research and Development Expense 193 193
32% 32%
37%
-308 -308
42% 42%
-60%
- Depreciation and Amortization 1.42 1.42
100% 100%
0%
EBIT (Operating Income) EBIT -310 -310
42% 42%
-60%
Net Profit -282 -282
45% 45%
-55%

In millions USD.

Don't miss a Thing! We will send you all news about Madrigal Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Madrigal Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
9 days ago
CONSHOHOCKEN, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on October 1, 2025 to 27 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Induce...
Positive
Seeking Alpha
16 days ago
MDGL's Rezdiffra is its main value driver. This is the first FDA-approved MASH F2–F3 therapy. So far, Rezdiffra shows a rapid U.S. uptake and market penetration. Management projects over 23,000 patients by Q2 2025. The EU also granted Rezdiffra a conditional authorization. It will soon launch in Germany, and it has a sizeable initial European target of diagnosed F2–F3 patients.
Neutral
GlobeNewsWire
28 days ago
CONSHOHOCKEN, Pa., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on September 15, 2025 to 76 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 In...
More Madrigal Pharmaceuticals, Inc. News

Company Profile

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Head office United States
CEO William Sibold
Employees 528
Founded 2011
Website www.madrigalpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today